STING1 and glioblastoma: Subsequent addition of anti-PD1 therapy to a STING agonist further improved survival in an immunologically “hot” murine model of glioblastoma, but not in an immunologically cold model, suggesting that additional immune modulation may be required to promote maximal antitumoral immune response in this setting (19).